Wize Pharma FCF/Debt
Delisted·Jan 10, 2019
The Free Cash Flow to Debt Ratio of Wize Pharma (WIZP) as of Aug 4, 2026 is -573.58 %.
Get this data via API
Financial Data API
FCF/Debt
-573.58 %
Last updated:
Free Cash Flow to Debt Ratio of Wize Pharma is 2026 -573.58 % . Free Cash Flow to Debt Ratio of Wize Pharma was 2025 0.00 . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
Wize Pharma Stock analysis
What does Wize Pharma do? Wize Pharma Inc. is a leading biopharmaceutical company specializing in the development and marketing of innovative products for the treatment of eye diseases. The company was founded in 1997 and is headquartered in Herzliya Pituach, Israel. It focuses on the research, development, manufacturing, and marketing of eye disease treatments. The company aims to become a leading brand in the field of eye health and offers high-quality services in eye care. Wize Pharma Inc. operates different divisions, with its main divisions being the development and marketing of eye therapeutics, including LO2A and LO2B. LO2A is an innovative therapy for dry eye, while LO2B is an intraoperative formulation used in glaucoma surgery. The company's products provide effective and sustainable solutions for the treatment of eye diseases. Wize Pharma is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Wize Pharma stock
Free Cash Flow to Debt Ratio of Wize Pharma is -573.58 % in 2026.
On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Wize Pharma since 2006 – with annual values, charts, and detailed analysis.
FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Wize Pharma with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
Leverage — Wize Pharma
All Key Metrics — Wize Pharma
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth